Возможности лозартана в ангиопротекции при гиперурикемии у пациентов с артериальной гипертензией

1. Ruilope LM, Garcia Puig J. Hyperuricemia and Renal Function. Current Hypertension Reports 2001; 3: 197-202.

2. Бритов А.Н. Вопросы профилактики и лечения гипертонии на популяционном уровне. Клин. медицина. 1984; 9.

3. Дроздов В.Н. Обмен мочевой кислоты у больных гипертонической болезнью с метаболическим синдромом. Автореф. дис. ... канд. мед. наук. М., 1999.

4. Кобалава Ж.Д. Клиническое и фармакодинамическое обоснование выбора антигипертензивных препаратов у больных эссенциальной гипертонией с сопутствующими факторами риска. Дис. ... д-ра мед. наук. М., 1997; с. 181, 216, 280, 292.

5. Riedel A, Nelson M. Prevalence of co morbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatology 2004; 10 (6): 308-14.

6. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20 (3): 369-79.

7. Bulpitt CJ. Serum uric acid in hypertensive patients. Br Heart J 1975; 37: 1210-5.

8. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.

9. Niskanen LK, Laaksonen DE, Nyyssonen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51.

10. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-6.

11. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002; 2: 126-30.

12. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg. Sweden Acta Med Scand 1988; 224: 549-55.

13. Ford ES, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526-32.

14. Bairaktari ET, Kakafika AI, Pritsivelis N et al. Hypouricemia in individuals admitted to an inpatient hospital-based facility. Am J Kidney Dis 2003; 41: 1225-32.

15. Goya Wannamethee S. Serum Uric Acid Is Not an Independent Risk Factor for Coronary Heart Disease. Current Hypertension Reports 2001; 3: 190-6.

16. Bagnati M, Perugini C, Cau C et al. When and why a water - soluble antioxidant becomes pro-oxidant during copper - induced low - density lipoprotein oxidation: a study using uric acid. Biochem J 1999; 340: 143-52.

17. Alderman MH. Serum Uric Acid As a Cardiovascular Risk Factor for Heart Disease. Current Hypertension Reports 2001; 3: 184-9.

18. Kerkalainen P, Sarlund H, Laakso M. Long-term association of cardiovascular risk factors with impaired insulin secretion and insulin resistance. Metabolism 2000; 49: 1247-54.

19. Hamada T, Hisatome I, Kinugasa Y et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002; 41: 793-7.

20. Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN 1997; 8: 322.

21. Shahinfar S, Simpson RL, Carides AD et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56: 1879-85.

22. Daskalopoulou SS et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66 (4): 1714-5.

23. Daijiro U, Hiroaki K. Long-term effects of angiotensin II receptor antagonist losartan on uric acid metabolism in hyperuricemic patients. Gout and Nucleic Acid Metabolism 2002; 26: 25-32.

24. Quarantino CP, Di Sciacio N, Rucci C et al. The normal range of serum urate levels and of fractional urate excretion. Adv Exp Med Biol 1994; 370: 91-3.

25. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-50.

26. Johnson RJ, Kivlighn SD, Kim YG et al. Reappraisal of the pathogenesis and consequences of hyperuricaemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33: 225-34.

27. Verdecchia P, Schillaci G, Reboldi GP et al. The relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The Piuma study. Hypertension 2000; 36: 1072-8.